Compare UTMD & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTMD | IPSC |
|---|---|---|
| Founded | 1978 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.4M | 189.7M |
| IPO Year | 1994 | 2021 |
| Metric | UTMD | IPSC |
|---|---|---|
| Price | $62.85 | $2.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 9.5K | ★ 941.3K |
| Earning Date | 04-30-2026 | 06-16-2026 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ 2.68 | N/A |
| Revenue | $40,903,000.00 | ★ $109,164,000.00 |
| Revenue This Year | N/A | $1,589.94 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $23.79 | $24.82 |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $51.27 | $0.34 |
| 52 Week High | $68.71 | $2.97 |
| Indicator | UTMD | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 42.35 | 56.92 |
| Support Level | $60.00 | $0.49 |
| Resistance Level | $64.21 | $2.71 |
| Average True Range (ATR) | 1.67 | 0.23 |
| MACD | -0.62 | 0.03 |
| Stochastic Oscillator | 11.79 | 51.50 |
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.